BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468


SEARCH JOBS

View Clinical Trials from BioPharm Insight

NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.


 Key Statistics


Email: employment@novabaypharma.com
Ownership:

Web Site: NovaBay Pharmaceuticals, Inc.
Employees:
Symbol: NBY
 









 Company News
NovaBay Pharmaceuticals, Inc. (NBY) Reports Second Quarter 2014 Financial Results And A Clinical/Business Update 7/31/2014 10:46:27 AM
NovaBay Pharmaceuticals, Inc. (NBY) Announces Direct US Marketing-Sales Campaign For New i-Lid™ Cleanser Product 7/16/2014 9:00:23 AM
Letter To NovaBay Pharmaceuticals, Inc. (NBY) Shareholders 7/11/2014 9:33:40 AM
NovaBay Pharmaceuticals, Inc. (NBY)’s New Product For Serious Eye Conditions Highlighted In CEOLIVE.TV Interview 7/3/2014 6:09:54 AM
NovaBay Pharmaceuticals, Inc. (NBY) Announces Presentation Of Positive Data From Its Clinical Trial Of Auriclosene Irrigation Solution For Urinary Catheter Encrustation And Blockage 5/20/2014 10:35:15 AM
NovaBay Pharmaceuticals, Inc. (NBY) Announces Presentation Of Positive Data From Its Clinical Trial Of Auriclosene Irrigation Solution For Urinary Catheter Encrustation And Blockage 5/20/2014 9:59:24 AM
NovaBay Pharmaceuticals, Inc. (NBY) Announces Completion Of Enrollment In Its Global Phase 2B Clinical Trial, BAYnovation 5/15/2014 8:48:23 AM
NovaBay Pharmaceuticals, Inc. (NBY) Reports First Quarter 2014 Financial Results And A Clinical/Business Update 5/1/2014 3:25:59 PM
Chronic Wounds Cost The Nation More Than $25 Billion Per Year, Reports Ron Najafi, CEO Of NovaBay Pharmaceuticals, Inc. (NBY) 4/29/2014 9:55:56 AM
NovaBay Pharmaceuticals, Inc. (NBY)' Neutrophase Is Focus Of Dr. John Crew's Presentation At Advanced Wound Care Symposium 4/24/2014 7:25:11 AM
12345678910...